Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2002-12-09
2010-11-23
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
Reexamination Certificate
active
07838555
ABSTRACT:
The present invention relates to the treatment of acnevulgarisin a subject by administering to the subject an ingenane of the formulawherein R24-R26are herein defined.
REFERENCES:
patent: 3809749 (1974-05-01), Persinos
patent: 4418064 (1983-11-01), Powell et al.
patent: 4560774 (1985-12-01), Pettit et al.
patent: 4716179 (1987-12-01), Hecker et al.
patent: 5145842 (1992-09-01), Driedger et al.
patent: 5643948 (1997-07-01), Driedger et al.
patent: 5716968 (1998-02-01), Driedger et al.
patent: 5750568 (1998-05-01), Driedger et al.
patent: 5874464 (1999-02-01), Marquez et al.
patent: 5886017 (1999-03-01), Driedger et al.
patent: 5886019 (1999-03-01), Driedger et al.
patent: 5891870 (1999-04-01), Driedger et al.
patent: 5891906 (1999-04-01), Driedger et al.
patent: 5932613 (1999-08-01), Jiang et al.
patent: 5962498 (1999-10-01), Driedger et al.
patent: 6432452 (2002-08-01), Aylward et al.
patent: 6787161 (2004-09-01), Aylward et al.
patent: 6844013 (2005-01-01), Aylward et al.
patent: 2003/0166613 (2003-09-01), Aylward et al.
patent: 2003/0171334 (2003-09-01), Aylward et al.
patent: 2003/0195168 (2003-10-01), Aylward et al.
patent: 2005/0003031 (2005-01-01), Aylward et al.
patent: 2005/0209192 (2005-09-01), Aylward et al.
patent: 1077129 (1993-10-01), None
patent: 1105246 (1995-09-01), None
patent: 1112011 (1995-11-01), None
patent: 1131037 (1996-09-01), None
patent: 29 02 506 (1979-01-01), None
patent: 41 02 054 (1992-07-01), None
patent: 0 455 271 (1991-11-01), None
patent: 0 330 094 (1999-08-01), None
patent: 8-13571 (1996-01-01), None
patent: 8-176002 (1996-07-01), None
patent: 8-245505 (1996-09-01), None
patent: WO 87/07599 (1987-12-01), None
patent: 87/07599 (1992-04-01), None
patent: WO 97/15575 (1997-05-01), None
patent: 99/08994 (1999-02-01), None
patent: WO 2005/065696 (2005-07-01), None
patent: WO 2006/063382 (2006-06-01), None
patent: WO 2007/053912 (2007-05-01), None
patent: WO 2007/068963 (2007-06-01), None
Kaminsky A. et al., “Euforbia y Cantaridina en el Tratamiento Topico de las Verrugas,” El Dia Medico, 31;1374-1380 (1959).
Hohmann, et al. “Jatrophane diterpenoids fromEuphorbia peplus”, Phytochemistry51: 673-677 (1999).
Hohmann, et al. “Diterpenoids fromEuphorbia peplus”, Planta Med.66: 291-294 (2000).
Alastair Aitken, et al., “The Activation of Protein Kinase C by Daphnane, Ingenane and Tigliane Diterpenoid Esters”,Botanical Journal of the Linnean Society,vol. 94 pp. 247-263 (1987).
Sahar El-Mekkawy, et al., “Anti-HIV-1 Phorbol Esters from the Seed ofCroton tiglium”, Phytochemistry,vol. 53 pp. 457-464, (2000).
Tian-Shung Wu, et al., “Antitumor Agents, 1191Kansuiphorins A and B, Two Novel Antileukemic Diterpene Esters FromEuphorbia kansui”, Journal of Natural Products, May-Jun. 1991, vol. 54, No. 3, pp. 823-829.
Salah M.A.D. Zayed, et al., “Dietary cancer risk from conditional cancerogens in produce of livestock fed on species of spruge (Euhorbiaceae) I. Skin irritant and tumor promoters of the ingenane diterpene ester type”, Cancer Res. Clin. Ocol, 1998, 124: pp. 131-140.
B D Curti “Physical barriers to drug delivery in tumors”, Critical Reviews in Oncology/Hematology, 1993; 14: pp. 29-39.
G B Dermer, Another Anniversary for the War on Cancer, Bio/Technology, Mar. 1994, vol. 12, p. 320.
T. Gura, “Systems for Identifying New Drugs are Often Faulty”, Science, Nov. 1997, vol. 278, pp. 1041-1042.
R.I. Freshney, “Culture of Animal Cells, A Manual of Basic Technique”, Department of Clinical Oncology, Cancer Research Campaign Laboratories, University Glasgow, (1983).
L H Hartwell et al., Integrating Genetic Approaches in the Discovery of Anticancer Drugs, Science, vol. 278, Nov. 7, 1997, pp. 1064-1068.
R K Jain, “Barriers to Drug Delivery in Solid Tumors”, Scientific American, Jul. 1994, pp. 58-65.
Extract from Endocrinology, Proceedings of the American Association for Cancer Research, vol. 36, Mar. 1995, p. 256.
Uemura D. et al., “New Diterpene, 13-Oxyingenol, Derivative Isolated FromEuphorbia kansuiLiou”,Tetrahedron Letters 29:2529-2532 (1974).
Kupchan S.M. et al., “Antileukemic Principles Isolated From Euphorbiaceae Plants”,Science 191:571-572 (1975).
Kupchan S.M. et al., “Gnidimacrin and Gnidimacrin 20-Palmitate, Novel Macrocyclic Antileukemic Diterpenoid Esters From Gnidia Subcordata”,Communications to the Editor5719-5720 (1976).
Evans F.J. et al., The Tigliane, Daphnane And Ingenane Diterpenes, Their Chemistry, Distribution And Biological Activities, A Review,Lloydia 41(3):193-233 (1978).
Hecker E., “Structure-Activity Relationships In Diterpene Esters Irritant And Cocarcinogenic To Mouse Skin”,Carcinogenesis 2:11-48 (1978).
Seip E.H. et al, “Skin Irritant Ingenol Esters FromEuphorbia esula”, Planta Medica 46:215-218 (1982).
Nishizuka Y., “The Role Of Protein Kinase C In Cell Surface Signal Transduction And Tumour Promotion”,Nature 308:693-698 (1984).
Schmidt R.J., “The Ingenane Polyol Esters”,Naturally Occurring Phorbol Esters, Boca Raton: CRC Press245-269 (1986).
Inoue S. et al., “Ingenane Synthetic Studies. Sterocontrolled Introduction Of All Oxygenated And Unsaturated Centers In An Ingenol Prototype”,J. Org. Chem. 52:5497-5498 (1987).
Hamamoto Y. et al., “Comparison Of Effects Of Protein Kinase C Inhibitors On Phorbol Ester-Induced CD4 Down-Regulation And Augmentation Of Human Immunodeficiency Virus Replication In Human T Cell Lines”,Biochemical and Biophysical Research Communications 164(1):339-344 (1989).
Chowdhury I.H. et al., “The Phorbol Ester TPA Strongly Inhibits HIV-1-Induced Syncytia Formation But Enhances Virus Production: Possible Involvement Of Protein Kinase C Pathway”,Virology 176:126-132 (1990).
Laurence J. et al., “Phorbol Ester-Mediated Induction of HIV-1 From A Chronically Infected Promonocyte Clone: Blockade By Protein Kinase Inhibitors And Relationship ToTat-DirectedTrans-Activation”,Biochemical and Biophysical Research Communications 166(1):349-357 (1990).
Krauter, et al., “Structure/activity relationships of polyfunctional diterpenes of tigliane type”, Eur. J. Biochem., 242, pp. 417-427 (1996).
El-Merzabani, et al., Planta Med. 1979 vol. 36, pp. 150-155.
M. Belkin,et al. “Tumor-Damaging Capacity of Plant Materials. I. Plants Used as Cathartics”, National Cancer Institute: Apr. 13, 1952, pp. 139-149.
D. Weedon, et al. “Home Treatment of Basil Cell Carcinoma”, Med. J. Aust., Jun. 1, 1976, p. 928.
Zayed, et al. J. Cancer Res. Clin. Oncol. 1998. vol. 124, pp. 301-308.
Benjamini, et al. Immunology—A Short Course. 1988, Publ: Allan R. Liss, Inc. NY. pp. 15-18.
Abo, K.A. Fitoterapia, 1988. vol. LIX, No. 3, pp. 244-246.
Derwent Abstract Accession No. 1992-206104/32, DE 4102054 A dated Jul. 30, 1992.
Biswas T.K. et al., “Plant Medicines of Indian Origin for Would Healing Activity: A Review”Lower Extremity Wounds2(1):25-39 (2003).
Natrajan D. et al., “Anti-bacterial activity ofEuphoria fusiformis—a rare medicinal herb”Journal of Enthopharmacology102: 123-126 (2005).
Betancur-Galvis LA et al., “Cytotoxic and Antiviral Activities of Colombian Medicinal Plant Extracts of theEuphorbiagenus”Memorias do Instituto Oswaldo Cruz97(4): 541-546 (2002).
Guarrera Paolo Maria, “Traditional pytotherapy in Central Italy”Fitoterapia76(1): 1-25 (2005).
Tropical Plant Database, Database File for AVELOZ (Euphorbia tirucalli) http://web.archive.org/web/20041030080015/http://www.rain-tree.com/aveloz.htm.
Ogbourne S. et al., “Proceedings of the First International Conference of PEP005”,Anti-Cancer Drugs18(3):357-362 (2007).
Weedon D. et al., “Home treatment of basal cell carcinoma”The Medical Journal of Australia1(24):928 (1976).
Jeeva S. et al., “Weeds of Kanyakumari district and their value in rural life”Indian Jo
Aylward James Harrison
Parsons Peter Gordon
Suhrbier Andreas
Turner Kathleen Anne
Peplin Research Pty Ltd
Scully , Scott, Murphy & Presser, P.C.
Spivack Phyllis G.
LandOfFree
Macrocyclic diterpenes for the treatment and prophylaxis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Macrocyclic diterpenes for the treatment and prophylaxis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic diterpenes for the treatment and prophylaxis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4219382